<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02648191</url>
  </required_header>
  <id_info>
    <org_study_id>1508013</org_study_id>
    <secondary_id>2015-A00253-46</secondary_id>
    <nct_id>NCT02648191</nct_id>
  </id_info>
  <brief_title>Preoperative Treatment With Noninvasive Intra-auricular Vagus Nerve Stimulation Pending Bariatric Surgery</brief_title>
  <acronym>OBESITE</acronym>
  <official_title>Preoperative Treatment With Noninvasive Intra-auricular Vagus Nerve Stimulation Pending Bariatric Surgery. A Randomized, Controlled, Double-blind Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondation de l'Avenir</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Faced with the current obesity epidemic, new avenues of research into effective weight loss
      must be developed.

      Among the possible actions on obesity, vagus nerve stimulation has been shown in several
      studies to be effective in treating epilepsy or depression, at the same time inducing weight
      loss in those patients. Vagus nerve stimulation has also shown to be effective on weight loss
      in experimental animal studies. Vagus nerve stimulation has never been attempted in obese
      patients awaiting bariatric surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to demonstrate the benefit of transcutaneous vagus nerve stimulation
      in obese subjects awaiting surgery. Secondary objectives include, among others, the risk
      factors related to obesity, systemic micro-inflammation, insulin and lipid profile.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2016</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight</measure>
    <time_frame>at 6 months</time_frame>
    <description>the weight (kg) is measured after 6 months of noninvasive stimulation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability (HRV)</measure>
    <time_frame>at 3, 6, 9 and 12 months</time_frame>
    <description>HRV is measured by a 24H-Holter Electrocardiography (ECG). It is a composite outcome :
the standard deviation of NN intervals (SDNN)
the proportion of number of pairs of successive NNs that differ by more than 50 ms, divided by total number of NNs (pNN50)
high frequency (HF)
low frequency (LF)
very low frequency (VLF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic inflammation</measure>
    <time_frame>at 3, 6, 9 and 12 months</time_frame>
    <description>Markers of systemic inflammation will be measured on centrifuged serum for C-reactive protein (CRP) and by immuno microassay using the Luminex method for InterLeukin (IL)-6 and IL-17.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apnea-hypopnea index (AHI)</measure>
    <time_frame>at 3, 6, 9 and 12 months</time_frame>
    <description>AHI is analyzed by a polysomnography in an outpatient setting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Health Questionnaire-9 (PHQ-9)</measure>
    <time_frame>at 3, 6, 9 and 12 months</time_frame>
    <description>It is a anxiety scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>at 1, 3, 6, 9 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Octanoylated ghrelin hormone</measure>
    <time_frame>at 3, 6, 9 and 12 months</time_frame>
    <description>Patients will be subjected to blood samplings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon-like peptide-1 hormone (GLP1)</measure>
    <time_frame>at 3, 6, 9 and 12 months</time_frame>
    <description>Patients will be subjected to blood samplings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peptide tyrosine tyrosine hormone (PYY)</measure>
    <time_frame>at 3, 6, 9 and 12 months</time_frame>
    <description>Patients will be subjected to blood samplings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipide profile (Cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglyceride)</measure>
    <time_frame>at 3, 6, 9 and 12 months</time_frame>
    <description>Patients will be subjected to blood samplings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum insulin level</measure>
    <time_frame>at 3, 6, 9 and 12 months</time_frame>
    <description>Patients will be subjected to blood samplings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemia</measure>
    <time_frame>at 3, 6, 9 and 12 months</time_frame>
    <description>Patients will be subjected to blood samplings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycated hemoglobin</measure>
    <time_frame>at 3, 6, 9 and 12 months</time_frame>
    <description>Patients will be subjected to blood samplings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>at 12 months</time_frame>
    <description>Local and systemic adverse effects will be described at each consultation. In particular, patients will be informed that they can call the investigator if they have any questions or to report any effects that seem unusual.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Obesity</condition>
  <condition>Bariatric Surgery</condition>
  <arm_group>
    <arm_group_label>Active stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Inactive stimulation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NeuroCoach II Stim</intervention_name>
    <description>A noninvasive vagus nerve stimulator consists of two components. An electrode is placed in the left ear concha and will be used by the patient for 4-5 hours per day in segments of 1 hour minimum.
For this intervention, the stimulations are active.</description>
    <arm_group_label>Active stimulation</arm_group_label>
    <other_name>NeuroCoach II Stim, NBA Techno, France</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NeuroCoach II Stim</intervention_name>
    <description>A noninvasive vagus nerve stimulator consists of two components. An electrode is placed in the left ear concha and will be used by the patient for 4-5 hours per day in segments of 1 hour minimum.
For this intervention, the stimulations are inactive.</description>
    <arm_group_label>Inactive stimulation</arm_group_label>
    <other_name>NeuroCoach II Stim, NBA Techno, France</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any obese patient consulting for bariatric surgery with BMI ≥ 35 and comorbidities or
             with BMI ≥ 40

          -  Consent Form signed

        Exclusion Criteria:

          -  Permanent atrial fibrillation

          -  Patient on treatment that could influence measurement of Autonomic Nervus System (ANS)
             activity (eg. anti-arrhythmics).

          -  For patients previously operated (by any technique), an interval of at least 6 months
             since the surgery must be observed

          -  Pacemaker

          -  Serious cardiac pathology

          -  History of myocardial infarction

          -  History of Stroke

          -  Severe respiratory insufficiency

          -  Allergy in the Rhodium and in the gold

          -  Surgery of the vagus nerve

          -  Pregnant patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Radwan KASSIR, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de St Etienne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Radwan KASSIR, MD</last_name>
    <phone>(0)477829353</phone>
    <phone_ext>+33</phone_ext>
    <email>radwan.kassir@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arnauld GARCIN, CRA</last_name>
    <phone>(0)477120286</phone>
    <phone_ext>+33</phone_ext>
    <email>arnauld.garcin@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Saint-Etienne</name>
      <address>
        <city>St Etienne</city>
        <zip>42000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Radwan KASSIR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Claude BARTHELEMY, MD-PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier TIFFET, MD-PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Luc BERGER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexia BOUEIL BOURLIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bogdan GALUSCA, MD-PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2016</study_first_submitted>
  <study_first_submitted_qc>January 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2016</study_first_posted>
  <last_update_submitted>October 26, 2017</last_update_submitted>
  <last_update_submitted_qc>October 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Bariatric Surgery</keyword>
  <keyword>No invasive intra-auricular vagus nerve stimulation</keyword>
  <keyword>Weight loss</keyword>
  <keyword>Autonomic nervous system</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

